Market Insight – GI adds stout to Ireland's life science melting pot
This article was originally published in Scrip
Executive Summary
A decade ago, Ireland's life sciences industry was somewhat at odds with itself. The country had attracted pharmaceutical giants to its shores and they duly set up manufacturing and development facilities. But it severely lacked an indigenous sector. These days, however, there is a throng of companies showcasing their work to the world and turning heads doing it. Simon Varcoe visited the country to explore how the home of that most medicinal of beers, Guinness, has shouldered its way onto the pharmaceutical scene.
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.